indications for glp 1 agonists Frontiers Beyond Blood Sugar: A Scoping

When ASCVD predominates: ASCVD is considered to predominate if a patient has established ASCVD or if they have indicators of high ASCVD risk

Key points: GLP-1s (glucagon-like peptide-1 receptor agonists) support type 2 diabetes by reducing appetite and supporting weight loss alongside their effects on the pancreas GLP-1-assisted programmes lead to a clinically significant weight loss of 10% or more, which can significantly reduce complications associated with obesity Combining semaglutide with lifestyle interventions leads to significantly more weight loss than lifestyle interventions alone, with 87% of participants losing more than 10% of their body weight Semaglutide is more effective at supporting weight loss than liraglutide Tirzepatide is more effective than semaglutide at reducing weight, with all three doses of tirzepatide leading to more significant weight loss than 1mg of semaglutide The higher doses of tirzepatide (10mg and 15mg) might reduce weight by 5.15kg more than 2mg of semaglutide, while there appears to be no difference between 5mg of tirzepatide and 2mg of semaglutide 3) Side effects and safety All medications have possible side effects, particularly if you live with other health conditions

Get in Touch with GenScript GLP-1 Receptor Agonist Service REQUEST A QUOTE

Pharmacies are having trouble keeping them in stock and patients are complaining that they cant get them

RDs also can advocate for the safe and proper use of weight management medications in tandem with promoting the critical roles of healthful eating, lifestyle modifications, and medication adherence

What are the drawbacks of GLP-1s